No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan

Infection. 2014 Dec;42(6):1065-6. doi: 10.1007/s15010-014-0677-2. Epub 2014 Aug 21.

Authors

D Focosi¹, L Macera, E Ciabatti, S Galimberti, M Petrini, A M Carella, M Pistello, L Ceccherini-Nelli, F Maggi

Affiliation

¹ Department of Translational Research, University of Pisa, via Paradisa 2, 56124, Pisa, Italy, [email protected].

PMID: 25143192
DOI: 10.1007/s15010-014-0677-2

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antibodies, Monoclonal, Murine-Derived / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Marrow / virology*
Chemoradiotherapy
Clinical Trials as Topic
Humans
JC Virus / physiology*
Lymphoma, Follicular / drug therapy
Lymphoma, Follicular / radiotherapy
Lymphoma, Follicular / therapy
Lymphoma, Follicular / virology*
Polyomavirus Infections / virology*
Radiopharmaceuticals / therapeutic use
Rituximab
Tumor Virus Infections / virology*
Virus Activation
Yttrium Radioisotopes / therapeutic use*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Radiopharmaceuticals
Yttrium Radioisotopes
Rituximab
ibritumomab tiuxetan